Tenderwize
Retour à la recherche

Conclusion of non-exclusive agreements for medicinal products with the active ingredient Relugolix (ATC code: L02BX04) via an Open-House model

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Dec 31, 2027 · 490 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Relugolix (ATC-Code: L02BX04) im Wege eines Open-House-Modells

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed minimum quantities; actual demand is uncertain and may be low.

Buyer may terminate the Open-House model early if exclusive agreements are concluded (typically 8-12 months after publi...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Supply of pharmaceutical products with active ingredient Relugolix (ATC L02BX04)
  • Non-exclusive agreements with AOK PLUS for the region of Saxony and Thuringia, Germany
Afficher le résumé complet

This tender is a non-exclusive Open-House model for pharmaceutical products containing Relugolix (ATC L02BX04). It allows any qualified pharmaceutical company to enter an agreement with AOK PLUS for supply to patients in Saxony and Thuringia, Germany. The notice is published for transparency but is not a formal EU procurement procedure. No estimated value is provided, and quantities are unknown. The agreement runs until 31 December 2027, with rolling submission deadlines starting 5 March 2026.

Risques

No guaranteed minimum quantities; actual demand is uncertain and may be low.

Buyer may terminate the Open-House model early if exclusive agreements are concluded (typically 8-12 months after publi...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined in §4(18) of the German Medicines Act (AMG)

Eligibility

  • Must submit a self-declaration of no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen)

Administrative

  • Must submit a self-declaration regarding Russia sanctions (Eigenerklärung Russlandsanktionen)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Not applicable (Open-House model)

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive agreements for medicinal products with the active ingredient Relugolix (ATC code: L02BX04) via an Open-House model

Non-exclusive agreements for supply of Relugolix to AOK PLUS. No minimum quantities, no exclusivity. Open to all qualifying pharmaceutical companies during the participation period.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Mar 2026 - Dec 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Not applicable (Open-House model)

Date limite

Expired Mar 05, 2026

Détails de la procédure

Date de publication
19 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
120686-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30